

Leila Dorling

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7762399/leila-dorling-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

974
citations

13
h-index

24
g-index

24
ext. papers

1,442
ext. citations

10.2
avg, IF

2.87
L-index

#	Paper	IF	Citations
21	Rare germline copy number variants (CNVs) and breast cancer risk.. <i>Communications Biology</i> , 2022 , 5, 65	6.7	0
20	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. <i>JAMA Oncology</i> , 2022 ,	13.4	4
19	Breast cancer risks associated with missense variants in breast cancer susceptibility genes.. <i>Genome Medicine</i> , 2022 , 14, 51	14.4	0
18	First international workshop of the ATM and cancer risk group (4-5 December 2019). <i>Familial Cancer</i> , 2021 , 1	3	5
17	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
16	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020 , 38, 674-685	2.2	133
15	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019 , 144, 1195-1204	7.5	18
14	Inherited mutations in and in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. <i>Journal of Medical Genetics</i> , 2018 , 55, 97-103	5.8	24
13	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. <i>Cancer Research</i> , 2018 , 78, 6329-6338	10.1	13
12	Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling. <i>Familial Cancer</i> , 2017 , 16, 51-56	3	12
11	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016 , 121, 431-439	5.3	69
10	Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity. <i>Clinical Cancer Research</i> , 2016 , 22, 1413-20	12.9	11
9	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. <i>PLoS ONE</i> , 2016 , 11, e0158984	3.7	7
8	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. <i>British Journal of Cancer</i> , 2016 , 114, 1165-74	8.7	12
7	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. <i>EBioMedicine</i> , 2016 , 10, 150-63	8.8	50
6	A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. <i>BMC Medicine</i> , 2015 , 13, 306	11.4	18
5	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. <i>Nature Genetics</i> , 2014 , 46, 891-4	36.3	92

4	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2014 , 111, 178-85	5.3	102
3	Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial. <i>Radiotherapy and Oncology</i> , 2014 , 111, 270-5	5.3	33
2	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. <i>Clinical Cancer Research</i> , 2014 , 20, 2466-75	12.9	78
1	Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4488-95	2.2	150